Pharmaceutical industry
As an exhausted and overworked medical student, I received a stream of gifts from pharmaceutical representatives, including expensive pens and textbook sets, which left me wondering about the nature of this relationship. My friend's comment that it's "behavioral science at its most basic" sparked
Drugs
The proposed merger between Glaxo Wellcome and SmithKline Beecham has created a pharmaceutical industry giant, valued at $163 billion, with combined sales of over $20 billion and sufficient research funds to develop new generations of drugs. This new alliance, led by Sir Richard Sykes, will position European pharmaceutical companies at
Drugs
The potential merger between Glaxo Wellcome PLC (GW) and SmithKline Beecham PLC (SB) has caught the attention of Standard & Poor's, which has placed their credit ratings on CreditWatch with positive implications. The proposed transaction, structured as a merger of equals, would combine two leading players in the
Pharmaceutical industry
Regional news sources reported on the emergence of a major pharmaceutical deal between British giants SmithKline Beecham PLC and Glaxo Wellcome PLC. The potential combination, which would create the world's largest pharmaceutical company, is currently at the negotiation stage. Financial details have not been disclosed, but if a
Pharmaceutical industry
The stock market experienced a significant increase on Tuesday, fueled by earnings reports that exceeded forecasts from major companies such as Walt Disney Co., Ford Motor Co., and Merck & Co. The Dow Jones industrial average, Standard & Poor's 500, and Nasdaq composite index all rose, with the
Drugs
SmithKline Beecham is mulling a Pounds 2.7 billion spin-off of SB Healthcare Services, a US clinics and pharmacy management operation, as part of its planned merger with American Home Products. This move is expected to be part of a Pounds 7 billion package of disposals, mostly from AHP, as
Drugs
Stocks surged on Tuesday as merger talks between pharmaceutical giants SmithKline Beecham Plc and American Home Products Corp. sparked speculation about potential acquisitions, while companies that reported better-than-expected earnings and recent mergers added to the market's gains. Drugmakers led the rally, with shares climbing to their biggest gain
Pharmaceutical industry
Regeneron Pharmaceuticals, Inc. has announced that George D. Yancopoulos, M.D., Ph.D., has been named the Company's Chief Scientific Officer, in addition to his role as Senior Vice President of Research. Dr. Yancopoulos joined Regeneron in 1989 and has led the Company's molecular and cell
Pharmaceutical industry
Fortune Brands Inc., the parent company of Jim Beam Brands Co., has unveiled a plan to cut costs, boost revenue, and improve sales of its major brands, including Moen faucets, Jim Beam bourbon, and Titleist golf equipment. The Old Greenwich, Conn.-based company expects to take larger-than-expected pretax restructuring charges
Pharmaceutical industry
Alexion Pharmaceuticals has announced that the United States Patent and Trademark Office has issued a patent (No. 5,705,732) related to the company's xenotransplantation program. This patent is exclusively licensed to Alexion and covers transgenic animals expressing a crucial human complement inhibitor known as CD59. The issuance
Pharmaceutical industry
Pharmacopeia, Inc., a leader in drug discovery, has achieved a significant research milestone in its collaboration with Daiichi Pharmaceutical Co., Ltd. As part of the agreement signed in March 1996, Daiichi has invested an additional $3 million in Pharmacopeia. This milestone marks a major achievement in the drug discovery process,
Drugs
Duramed Pharmaceuticals Inc. has gained approval from the US Food and Drug Administration to market its first female hormonal product, Estradiol, paving the way for increased sales and profits. The company's entry into the market for female hormonal replacement drugs marks a significant milestone in its development pipeline.
